Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glofitamab + pirtobrutinib
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Glofitamab + pirtobrutinib is a combination regimen under investigation for the treatment of relapsed or refractory mantle cell lymphoma (MCL). Glofitamab is a bispecific monoclonal antibody that simultaneously targets CD20 on B-cells and CD3 on T-cells, promoting T-cell-mediated cytotoxicity against malignant B-cells. Pirtobrutinib is a non-covalent, reversible small molecule inhibitor of Bruton's tyrosine kinase (BTK), blocking B-cell receptor (BCR) signaling and impeding proliferation and survival of malignant B-cells, including those with mutations conferring resistance to other BTK inhibitors. The combination aims to provide additive or synergistic antitumor activity and is currently being studied in clinical trials for relapsed/refractory MCL, particularly in patients previously treated with covalent BTK inhibitors[1][2][3][5][7].
- Other names
- glofitamab plus pirtobrutinib
02
Targets
Beyond the preview
Go deeper on glofitamab + pirtobrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glofitamab + pirtobrutinib.